Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2875 entries
Sorted by: Best Match Show Resources per page
Disseminated intravascular coagulation.

Indian journal of anaesthesia

Venugopal A.
PMID: 25535423
Indian J Anaesth. 2014 Sep;58(5):603-8. doi: 10.4103/0019-5049.144666.

Disseminated intravascular coagulation (DIC) is a reflection of an underlying systemic disorder which affects the coagulation system, simultaneously resulting in pro-coagulant activation, fibrinolytic activation, and consumption coagulopathy and finally may result in organ dysfunction and death. Though septicaemia is...

Cite
Venugopal A. Disseminated intravascular coagulation. Indian J Anaesth. 2014;58(5):603-8doi: 10.4103/0019-5049.144666.
Venugopal, A. (2014). Disseminated intravascular coagulation. Indian journal of anaesthesia, 58(5), 603-8. https://doi.org/10.4103/0019-5049.144666
Venugopal, A. "Disseminated intravascular coagulation." Indian journal of anaesthesia vol. 58,5 (2014): 603-8. doi: https://doi.org/10.4103/0019-5049.144666
Venugopal A. Disseminated intravascular coagulation. Indian J Anaesth. 2014 Sep;58(5):603-8. doi: 10.4103/0019-5049.144666. PMID: 25535423; PMCID: PMC4260307.
Copy Download .nbib Format: NLM
The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin.

Immunology today

Cambier JC, Monroe JG, Mark Coggeshall K, Ransom JT.
PMID: 25290184
Immunol Today. 1985 Jul;6(7):218-22. doi: 10.1016/0167-5699(85)90038-6.

The specificity of humoral immune responses is determined primarily at the level of antigen interaction with B lymphocytes which express antigen-specific receptor immunoglobulin. When receptor immunoglobulin is crosslinked by antigen or anti-receptor antibodies there isgeneration and transduction of signals...

Cite
Cambier JC, Monroe JG, Mark Coggeshall K, et al. The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin. Immunol Today. 1985;6(7):218-22doi: 10.1016/0167-5699(85)90038-6.
Cambier, J. C., Monroe, J. G., Mark Coggeshall, K., & Ransom, J. T. (1985). The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin. Immunology today, 6(7), 218-22. https://doi.org/10.1016/0167-5699(85)90038-6
Cambier, J C, et al. "The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin." Immunology today vol. 6,7 (1985): 218-22. doi: https://doi.org/10.1016/0167-5699(85)90038-6
Cambier JC, Monroe JG, Mark Coggeshall K, Ransom JT. The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin. Immunol Today. 1985 Jul;6(7):218-22. doi: 10.1016/0167-5699(85)90038-6. PMID: 25290184.
Copy Download .nbib Format: NLM
Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets.

Journal of cheminformatics

García-Jacas CR, Contreras-Torres E, Marrero-Ponce Y, Pupo-Meriño M, Barigye SJ, Cabrera-Leyva L.
PMID: 26925168
J Cheminform. 2016 Feb 25;8:10. doi: 10.1186/s13321-016-0122-x. eCollection 2016.

BACKGROUND: Recently, novel 3D alignment-free molecular descriptors (also known as QuBiLS-MIDAS) based on two-linear, three-linear and four-linear algebraic forms have been introduced. These descriptors codify chemical information for relations between two, three and four atoms by using several (dis-)similarity...

Cite
García-Jacas CR, Contreras-Torres E, Marrero-Ponce Y, et al. Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets. J Cheminform. 2016;8:10doi: 10.1186/s13321-016-0122-x.
García-Jacas, C. R., Contreras-Torres, E., Marrero-Ponce, Y., Pupo-Meriño, M., Barigye, S. J., & Cabrera-Leyva, L. (2016). Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets. Journal of cheminformatics, 810. https://doi.org/10.1186/s13321-016-0122-x
García-Jacas, César R, et al. "Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets." Journal of cheminformatics vol. 8 (2016): 10. doi: https://doi.org/10.1186/s13321-016-0122-x
García-Jacas CR, Contreras-Torres E, Marrero-Ponce Y, Pupo-Meriño M, Barigye SJ, Cabrera-Leyva L. Examining the predictive accuracy of the novel 3D N-linear algebraic molecular codifications on benchmark datasets. J Cheminform. 2016 Feb 25;8:10. doi: 10.1186/s13321-016-0122-x. eCollection 2016. PMID: 26925168; PMCID: PMC4768433.
Copy Download .nbib Format: NLM
Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach.

Cureus

Chintalacheruvu LM, Bhatty O, Andukuri VG.
PMID: 28924530
Cureus. 2017 Jul 07;9(7):e1444. doi: 10.7759/cureus.1444.

In the last few decades many new anticoagulants (i.e direct thrombin and factor ten inhibitors) have been introduced with efficacy that rivals older drugs in the treatment of venous thromboembolism (VTE). However, for all their success, management of patients...

Cite
Chintalacheruvu LM, Bhatty O, Andukuri VG. Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus. 2017;9(7):e1444doi: 10.7759/cureus.1444.
Chintalacheruvu, L. M., Bhatty, O., & Andukuri, V. G. (2017). Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus, 9(7), e1444. https://doi.org/10.7759/cureus.1444
Chintalacheruvu, Lakshmi Manogna, et al. "Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach." Cureus vol. 9,7 (2017): e1444. doi: https://doi.org/10.7759/cureus.1444
Chintalacheruvu LM, Bhatty O, Andukuri VG. Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach. Cureus. 2017 Jul 07;9(7):e1444. doi: 10.7759/cureus.1444. PMID: 28924530; PMCID: PMC5589500.
Copy Download .nbib Format: NLM
Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia.

Lancet (London, England)

José R, Williams A, Sulikowski M, Brealey D, Brown J, Chambers R.
PMID: 26312874
Lancet. 2015 Feb 26;385:S52. doi: 10.1016/S0140-6736(15)60367-1.

BACKGROUND: Community-acquired pneumonia is commonly caused by Streptococcus pneumoniae, which is associated with excessive neutrophilic inflammation. The high-affinity thrombin receptor, proteinase-activated receptor 1 (PAR1), has been implicated in mediating the interplay between coagulation and inflammation. However, its role during...

Cite
José R, Williams A, Sulikowski M, et al. Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. Lancet. 2015;385:S52doi: 10.1016/S0140-6736(15)60367-1.
José, R., Williams, A., Sulikowski, M., Brealey, D., Brown, J., & Chambers, R. (2015). Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. Lancet (London, England), 385S52. https://doi.org/10.1016/S0140-6736(15)60367-1
José, Ricardo, et al. "Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia." Lancet (London, England) vol. 385 (2015): S52. doi: https://doi.org/10.1016/S0140-6736(15)60367-1
José R, Williams A, Sulikowski M, Brealey D, Brown J, Chambers R. Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia. Lancet. 2015 Feb 26;385:S52. doi: 10.1016/S0140-6736(15)60367-1. PMID: 26312874.
Copy Download .nbib Format: NLM
A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action.

Biophysical reviews

Winzor DJ.
PMID: 28510155
Biophys Rev. 2013 Jun;5(2):173-185. doi: 10.1007/s12551-013-0103-5. Epub 2013 Feb 14.

Difficulties are encountered in the thermodynamic characterization of interactions between a protein ligand and a linear acceptor, such as a polynucleotide or a polysaccharide, because of the involvement of more than one unit of the polymer chain in each...

Cite
Winzor DJ. A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action. Biophys Rev. 2013;5(2):173-185doi: 10.1007/s12551-013-0103-5.
Winzor, D. J. (2013). A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action. Biophysical reviews, 5(2), 173-185. https://doi.org/10.1007/s12551-013-0103-5
Winzor, Donald J. "A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action." Biophysical reviews vol. 5,2 (2013): 173-185. doi: https://doi.org/10.1007/s12551-013-0103-5
Winzor DJ. A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action. Biophys Rev. 2013 Jun;5(2):173-185. doi: 10.1007/s12551-013-0103-5. Epub 2013 Feb 14. PMID: 28510155; PMCID: PMC5425718.
Copy Download .nbib Format: NLM
Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study).

Journal of arrhythmia

Kusakawa K, Harada KH, Kagimura T, Koizumi A.
PMID: 28416974
J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11.

BACKGROUND: Oral anticoagulants (OACs) can help prevent stroke in patients with nonvalvular atrial fibrillation (NVAF). The aim of this study was to characterize the use of OACs other than direct thrombin inhibitors (DTIs) for NVAF.METHODS: Patients with NVAF taking...

Cite
Kusakawa K, Harada KH, Kagimura T, et al. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2016;33(2):99-106doi: 10.1016/j.joa.2016.06.006.
Kusakawa, K., Harada, K. H., Kagimura, T., & Koizumi, A. (2017). Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). Journal of arrhythmia, 33(2), 99-106. https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa, Koichi, et al. "Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study)." Journal of arrhythmia vol. 33,2 (2017): 99-106. doi: https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa K, Harada KH, Kagimura T, Koizumi A. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11. PMID: 28416974; PMCID: PMC5388034.
Copy Download .nbib Format: NLM
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Journal of blood medicine

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG.
PMID: 28979172
J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017.

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent...

Cite
Kaatz S, Bhansali H, Gibbs J, et al. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017;8:141-149doi: 10.2147/JBM.S121550.
Kaatz, S., Bhansali, H., Gibbs, J., Lavender, R., Mahan, C. E., & Paje, D. G. (2017). Reversing factor Xa inhibitors - clinical utility of andexanet alfa. Journal of blood medicine, 8141-149. https://doi.org/10.2147/JBM.S121550
Kaatz, Scott, et al. "Reversing factor Xa inhibitors - clinical utility of andexanet alfa." Journal of blood medicine vol. 8 (2017): 141-149. doi: https://doi.org/10.2147/JBM.S121550
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. PMID: 28979172; PMCID: PMC5602457.
Copy Download .nbib Format: NLM
Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke.

Journal of stroke

Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, Kwon SU, Bae HJ, Heo JH, Lee BC, Yoon BW.
PMID: 26060808
J Stroke. 2015 May;17(2):210-5. doi: 10.5853/jos.2015.17.2.210. Epub 2015 May 29.

Cardioembolic stroke related to nonvalvular atrial fibrillation is associated with a high recurrence rate and high mortality and morbidity. In this population, therefore, optimal anticoagulant therapy is required to prevent the occurrence of second stroke. Oral anticoagulant, warfarin has...

Cite
Jung KH, Yu KH, Kim YD, et al. Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke. 2015;17(2):210-5doi: 10.5853/jos.2015.17.2.210.
Jung, K. H., Yu, K. H., Kim, Y. D., Park, J. M., Hong, K. S., Rha, J. H., Kwon, S. U., Bae, H. J., Heo, J. H., Lee, B. C., & Yoon, B. W. (2015). Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. Journal of stroke, 17(2), 210-5. https://doi.org/10.5853/jos.2015.17.2.210
Jung, Keun-Hwa, et al. "Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke." Journal of stroke vol. 17,2 (2015): 210-5. doi: https://doi.org/10.5853/jos.2015.17.2.210
Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, Kwon SU, Bae HJ, Heo JH, Lee BC, Yoon BW. Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke. 2015 May;17(2):210-5. doi: 10.5853/jos.2015.17.2.210. Epub 2015 May 29. PMID: 26060808; PMCID: PMC4460340.
Copy Download .nbib Format: NLM
Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever.

The Eurasian journal of medicine

Ozkurt Z, Ozden K, Kiki I, Usanmaz M.
PMID: 25610169
Eurasian J Med. 2011 Aug;43(2):83-6. doi: 10.5152/eajm.2011.19.

OBJECTIVE: Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhagic fever. Disseminated intravascular coagulation (DIC) is an important complication of this disease, especially in severe and fatal cases. Antithrombin (AT) acts as an anticoagulant by inactivating thrombin, Factor IX,...

Cite
Ozkurt Z, Ozden K, Kiki I, et al. Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever. Eurasian J Med. 2011;43(2):83-6doi: 10.5152/eajm.2011.19.
Ozkurt, Z., Ozden, K., Kiki, I., & Usanmaz, M. (2011). Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever. The Eurasian journal of medicine, 43(2), 83-6. https://doi.org/10.5152/eajm.2011.19
Ozkurt, Zulal, et al. "Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever." The Eurasian journal of medicine vol. 43,2 (2011): 83-6. doi: https://doi.org/10.5152/eajm.2011.19
Ozkurt Z, Ozden K, Kiki I, Usanmaz M. Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever. Eurasian J Med. 2011 Aug;43(2):83-6. doi: 10.5152/eajm.2011.19. PMID: 25610169; PMCID: PMC4261357.
Copy Download .nbib Format: NLM
Global assays and the management of oral anticoagulation.

Thrombosis journal

Brinkman HJ.
PMID: 25762867
Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015.

Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of...

Cite
Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015;13:9doi: 10.1186/s12959-015-0037-1.
Brinkman, H. J. (2015). Global assays and the management of oral anticoagulation. Thrombosis journal, 139. https://doi.org/10.1186/s12959-015-0037-1
Brinkman, Herm Jan M. "Global assays and the management of oral anticoagulation." Thrombosis journal vol. 13 (2015): 9. doi: https://doi.org/10.1186/s12959-015-0037-1
Brinkman HJ. Global assays and the management of oral anticoagulation. Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015. PMID: 25762867; PMCID: PMC4355453.
Copy Download .nbib Format: NLM
[No title available]

Research in pharmaceutical sciences

Sajjadi SM, Rahimi H, Mohammadi S, Faranoush M, Mirzahoseini H, Toogeh G.
PMID: 28255315
Res Pharm Sci. 2017 Feb;12(1):60-66. doi: 10.4103/1735-5362.199048.

Hirudin is an anticoagulant agent of the salivary glands of the medicinal leech. Recombinant hirudin (r-Hir) displays certain drawbacks including bleeding and immunogenicity. To solve these problems, cysteine-specific PEGylation has been proposed as a successful technique. However, proper selection...

Cite
Sajjadi SM, Rahimi H, Mohammadi S, et al. . Res Pharm Sci. 2017;12(1):60-66doi: 10.4103/1735-5362.199048.
Sajjadi, S. M., Rahimi, H., Mohammadi, S., Faranoush, M., Mirzahoseini, H., & Toogeh, G. (2017). . Research in pharmaceutical sciences, 12(1), 60-66. https://doi.org/10.4103/1735-5362.199048
Sajjadi, Seyed Mehdi, et al. "." Research in pharmaceutical sciences vol. 12,1 (2017): 60-66. doi: https://doi.org/10.4103/1735-5362.199048
Sajjadi SM, Rahimi H, Mohammadi S, Faranoush M, Mirzahoseini H, Toogeh G. . Res Pharm Sci. 2017 Feb;12(1):60-66. doi: 10.4103/1735-5362.199048. PMID: 28255315; PMCID: PMC5333481.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2875 entries